Oppenheimer Has Lowered Expectations for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its price target decreased by Oppenheimer from $190.00 to $180.00 in a research report report published on Friday,Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Several other brokerages also recently issued reports on ASND. JPMorgan Chase & Co. decreased their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Wedbush reiterated an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday. Finally, Evercore ISI raised their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Price Performance

ASND opened at $126.51 on Friday. The company has a 50 day simple moving average of $132.30 and a two-hundred day simple moving average of $132.60. The firm has a market cap of $7.67 billion, a P/E ratio of -15.66 and a beta of 0.66. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Equities analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after purchasing an additional 4,338 shares during the period. Evolutionary Tree Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 82.3% during the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 11,223 shares during the period. SG Americas Securities LLC grew its holdings in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after purchasing an additional 4,205 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.